Lauren Jelley

Lauren Jelley

Auto-generated profile, based on publicly available information

Lauren Jelley

Institute of Environmental Science and Research , Wellington

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2025 in Eurosurveillance
Verified
Journal Article
Open access
CDClyde Dapat
Clyde Dapat
HPHeidi Peck
Heidi Peck
LJLauren Jelley
Lauren Jelley
TDTanya Diefenbach-Elstob
Tanya Diefenbach-Elstob
TSTegan Slater
Tegan Slater
Ian BarrIan Barr
Ian Barr
In Australia and New Zealand, late outbreaks of an A(H3N2) variant virus termed subclade K extended the 2025 influenza season. Subclade K viruses were genetically and antigenically distinct from the 2025 vaccine A(H3N2) strain A/Croatia/10136RV/2023 (H3N2)-like virus and previously circulating subclade J viruses. Subclade K viruses have since been detected in over 34 countries and appear to have spread globally, except in South America. It is thus likely that they will further expand during the northern hemisphere winter 2025/26 season.

15 July 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
NANayyereh Aminisani
Nayyereh Aminisani
BFBriony Fanslow
Briony Fanslow
TWTimothy Wood
Timothy Wood
LJLauren Jelley
Lauren Jelley
LTLouise Thorn
Louise Thorn
QHQ Sue Huang
Q Sue Huang
Background: Understanding temporal trends of influenza and human metapneumovirus (HMPV) infections among adults and their return after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]) pandemic is important for designing prevention and control strategies. Methods: Using the New Zealand hospital-based surveillance dataset, we compared the population-based incidence, seasonality, and clinical characteristics of influenza and HMPV infections among hospitalized adults aged 20 years and older with acute respiratory infections (ARI) in Auckland, New Zealand, from 2012 to 2023. Results: In the surveillance project, 37 185 ARI hospitalizations were detected from 2012 to 2023 among adults 20 years and older. Of the 21 649 illnesses tested for HMPV, 735 (3.4%) were positives and of the 24 138 tested for influenza, 3623 (15.0%) were positives. Crude rates of annual ARI hospitalizations per 100 000 adult residents were 9.7 (95% confidence interval [CI], 9–10.4) for HMPV and 48.2 (95% CI, 46.6–49.7) for influenza. The highest hospitalization rates for both viruses were in those aged 80 years or older, those of Māori or Pacific ethnicity, and those living in low socioeconomic status areas. There were no statistically significant differences in the HMPV-associated ARI hospitalization rates before and after the COVID-19 pandemic. In contrast, influenza-associated hospitalization rates per 100 000 were 43.0 before the pandemic, increased to 54.4 in 2022, and then 79.5 in 2023, with significant increases across most demographic groups. Conclusions: Although HMPV infections accounted for fewer ARI hospitalizations than influenza infections in all study years, relative to younger adults, HMPV-associated ARI hospitalization rates were significantly higher in older adults due to the high prevalence of underlying chronic conditions in this age group. This highlights a need for vaccine/antiviral intervention.

15 July 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
NANayyereh Aminisani
Nayyereh Aminisani
TWTimothy Wood
Timothy Wood
BWBen Waite
Ben Waite
RSRuth Seeds
Ruth Seeds
LJLauren Jelley
Lauren Jelley
QHQ Sue Huang
Q Sue Huang
Background: Unlike influenza, information on the risk of human metapneumovirus (HMPV) infections in adults with chronic medical conditions (CMCs) is less robust. Methods: The SHIVERS project (Southern Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance) performed a population-based surveillance of acute respiratory illness hospitalizations in Auckland, New Zealand, from 2012 to 2015. In this analysis, we linked these surveillance data to population-based administrative data to estimate the age- and ethnicity-adjusted risk of HMPV-associated hospitalization during the study period among adults by certain CMCs: chronic obstructive pulmonary disease, asthma, congestive heart failure, coronary artery disease, cerebrovascular accidents, diabetes mellitus, and end-stage renal disease. Results: Overall, HMPV hospitalization rates were significantly higher across all ages and ethnic groups among adults with CMCs than those without any condition. In imputed analysis, the CMC with the highest risk of HMPV hospitalization across age groups was congestive heart failure (incidence rate ratio [IRR] range, 7.0–23.0), followed by coronary artery disease (IRR range, 4.2–9.1) and chronic obstructive pulmonary disease (IRR range, 6.7–11.9) in adults aged ≥50 years. The CMC with the highest risk of HMPV hospitalization was congestive heart failure in Māori/Pacific adults and chronic obstructive pulmonary disease in non-Māori/Pacific adults. Adults with ≥2 CMCs had a higher risk than those without CMCs; the risk varied by age group and ethnicity. Conclusions: Adults with specific or ≥2 CMCs are at increased risk of HMPV hospitalizations. Age and ethnicity affect this relationship for some CMCs but not all. Such populations may benefit from future HMPV prevention strategies.

24 February 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
QHQ Sue Huang
Q Sue Huang
TWTim Wood
Tim Wood
NANayyereh Aminisani
Nayyereh Aminisani
AKAmanda Kvalsvig
Amanda Kvalsvig
MBMichael Baker
Michael Baker
RWRichard J Webby
Richard J Webby
Background: While severe outcomes among hospitalized patients with COVID-19 and influenza are well described, comparative studies are lacking on community transmission and milder illnesses associated with COVID-19 and influenza. Methods: This study is based on a prospective community cohort in Wellington, New Zealand, consisting of participants with acute respiratory illness associated with COVID-19 and influenza, as confirmed by polymerase chain reaction. From 7 February to 2 October 2022, we compared the incidence, risk/protective factors, and clinical features among them. Results: The crude incidence of COVID-19–associated acute respiratory illness was 59 per 100 person-years (PY). The adjusted cumulative incidence for COVID-19 (77/100 PY; 95% CI, 75–80) was 4.5 times higher than for influenza (17/100 PY; 95% CI, 15–19). Among all COVID-19 cases, the proportion of children aged 0 to 17 years with COVID-19 was substantial but smaller than those of influenza (402/1229 [33%] vs 173/255 [68%], P < .0001). The highest incidence of COVID-19 was among adolescents aged 12 to 17 years (109/100 PY; 95% CI, 97–119) and individuals who were European and other ethnicity (83/100 PY; 95% CI, 80–86), whereas the highest influenza incidence was among children aged 1 to 4 years (49/100 PY; 95% CI, 40–58) and Māori (35/100 PY; 95% CI, 28–43). Adolescents aged 12 to 17 years had 2.5-times higher peak COVID-19 incidence (5.9/100) than adults aged ≥18 years (2.4/100). Adolescents with 2 doses of the COVID-19 vaccines had 75% greater risk of COVID-19 infection (hazard ratio, 1.75; 95% CI, 1.40–2.20) as compared with adults with 3 doses. Vaccination, age, ethnicity, and household size were independent protective/risk factors for COVID-19 or influenza. Participants with COVID-19, as compared with influenza, were less likely to access health care or experience febrile and severe illnesses but more likely to report sore throat, headache, myalgia, and taste or smell loss. Conclusions: As the world transitions to COVID-19 endemicity, estimating disease burdens in community settings becomes important to understand complete disease pyramids, risk factors, and clinical progression for informing countermeasures.